Survival following relapse in children with acute myeloid leukemia: A report from aml-bfm and cog
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F21%3A10427710" target="_blank" >RIV/00064203:_____/21:10427710 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/21:10427710
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=agvUP238l2" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=agvUP238l2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers13102336" target="_blank" >10.3390/cancers13102336</a>
Alternative languages
Result language
angličtina
Original language name
Survival following relapse in children with acute myeloid leukemia: A report from aml-bfm and cog
Original language description
Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 +- 4% (BFM) and 35 +- 2% (COG). Initial high-risk features (BFM 32 +- 6%, COG 26 +- 4%) and short time to relapse (BFM 29 +- 4%, COG 25 +- 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 +- 7% vs. 63 +- 10%, p = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 +- 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancers
ISSN
2072-6694
e-ISSN
—
Volume of the periodical
13
Issue of the periodical within the volume
10
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
2336
UT code for WoS article
000654663900001
EID of the result in the Scopus database
2-s2.0-85105667905